BioInvent Recruits Michael Oredsson as New CEO
News May 24, 2013
BioInvent International AB has announced that the Company's Board of Directors has appointed Michael Oredsson as new President and CEO.
Michael Oredsson has a degree in International Business Administration and has for many years held senior executive positions in the pharmaceutical and biotech industry.
He is currently the CEO of Probi AB and has held his earlier executive positions at, among others, Pharmacia Corporation.
BioInvent’s chairman Björn O. Nilsson says in a comment "We are very pleased to have been able to recruit a new CEO with a broad and international experience from different parts of the life science industry. We are confident that Michael's expertise and experience of licenses, contracts and commercial solutions and collaborations will be of great importance for our new strategic direction, which include increased focus on developing existing and new alliances with partners based on our technology platform and project portfolio."
"BioInvent is a very interesting company with broad knowledge, strong technologies and numerous partnerships in the field of antibody therapeutics. The company's new strategy provides exciting opportunities and I look forward to leading this work, "says Michael Oredsson.
Cold and Flu Season is Well Under Way But Don't Stifle a Sneeze Warn DoctorsNews
Pinching your nose while clamping your mouth shut to contain a forceful sneeze isn't a good idea, warn doctors. One young man managed to rupture the back of his throat during this manoeuvre, leaving him barely able to speak or swallow, and in considerable pain.READ MORE
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE
Immunosuppressive Cells in Newborns Play Important Role in Controlling Inflammation in Early LifeNews
New research has characterized the transitory presence of myeloid-derived suppressor cells (MDSCs) in mouse and human newborns, revealing a critical role of these cells in regulation of inflammation in the early stages of life.READ MORE